European Union - English - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccines - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty original/omicron ba.1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19.comirnaty original/omicron ba.4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.comirnaty original/omicron ba.4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.comirnaty original/omicron ba.4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba.4-5 (1.5/1.5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty omicron xbb.1.5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.comirnaty omicron xbb.1.5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.comirnaty omicron xbb.1.5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.comirnaty omicron xbb.1.5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.the use of this vaccine should be in accordance with official recommendations.

Kenya - English - Pharmacy and Poisons Board

single-stranded, 5’-capped messenger rna (mrna)… - injection - 30 micrograms of covid-19 mrna vaccine (embedded… - covid-19 vaccines

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - riltozinameran, quantity: 50 microgram/ml; tozinameran, quantity: 50 microgram/ml - injection, suspension - excipient ingredients: water for injections; distearoylphosphatidylcholine; trometamol; trometamol hydrochloride; sucrose; 2-((polyethylene glycol)-2000)-n-n-ditetradecylacetamide; ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate); cholesterol - comirnaty original/omicron ba.1 vaccine has provisional approval for the indication below: as a booster dose for active immunisation to prevent coronavirus disease 2019 (covid-19) caused by sars-cov-2, in individuals 18 years of age and older. the use of this vaccine should be in accordance with official recommendations. the decision has been made on the basis of short term immunogenicity and safety data. continued approval depends on the evidence of longer term efficacy and safety from ongoing clinical trials and post-market assessment.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tozinameran, quantity: 50 microgram/ml; famtozinameran, quantity: 50 microgram/ml - injection, suspension - excipient ingredients: cholesterol; sucrose; distearoylphosphatidylcholine; ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate); 2-((polyethylene glycol)-2000)-n-n-ditetradecylacetamide; trometamol hydrochloride; water for injections; trometamol - comirnaty original/omicron ba.4-5 vaccine has provisional approval for the indication below:,active immunisation to prevent coronavirus disease 2019 (covid-19) caused by sars-cov- 2, in individuals12 years of age and older.,the use of this vaccine should be in accordance with official recommendations.,the decision has been made on the basis of short term immunogenicity and safety data. continued approval depends on the evidence of longer term efficacy and safety from ongoing clinical trials and post-market assessment.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - tozinameran 0.5 mg/ml equivalent to 30 µg/0.3ml dose;  ;  ;  ;  ; tozinameran 0.5 mg/ml equivalent to 30 µg/0.3 ml dose - concentrate for injection - 0.5 mg/ml - active: tozinameran 0.5 mg/ml equivalent to 30 µg/0.3ml dose         excipient: 1,2-distearoyl-sn-glycero-3-phosphocholine alc-0159 alc-0315 cholesterol dibasic sodium phosphate dihydrate monobasic potassium phosphate potassium chloride sodium chloride sucrose water for injection active: tozinameran 0.5 mg/ml equivalent to 30 µg/0.3 ml dose excipient: 1,2-distearoyl-sn-glycero-3-phosphocholine alc-0159 alc-0315 cholesterol dibasic sodium phosphate dihydrate hydrochloric acid monobasic potassium phosphate potassium chloride sodium chloride sodium hydroxide sucrose water for injection - active immunisation to prevent coronavirus disease 2019 (covid-19) caused by sars-cov-2, in individuals 12 years of age and older. the use of this vaccine should be in accordance with official recommendations.

Israel - English - Ministry of Health

pfizer pharmaceuticals israel ltd - covid-19 mrna vaccine - concentrate for dispersion for injection - covid-19 mrna vaccine 0.5 mg/ml - covid-19 vaccines - comirnaty is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 virus, in individuals 12 years of age and older.

Israel - English - Ministry of Health

pfizer pharmaceuticals israel ltd - covid-19 mrna vaccine - concentrate for dispersion for injection - covid-19 mrna vaccine 0.5 mg/ml - covid-19 vaccines - comirnaty is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 virus, in individuals 12 years of age and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tozinameran, quantity: 40 microgram - injection, concentrated - excipient ingredients: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate); water for injections; cholesterol; 2-((polyethylene glycol)-2000)-n-n-ditetradecylacetamide; sucrose; distearoylphosphatidylcholine; trometamol; trometamol hydrochloride - active immunisation to prevent coronavirus disease 2019 (covid-19) caused by sars-cov-2, in individuals 6 months of age to less than 5 years of age.,the use of this vaccine should be in accordance with official recommendations.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tozinameran, quantity: 225 microgram - injection, suspension - excipient ingredients: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate); water for injections; cholesterol; 2-((polyethylene glycol)-2000)-n-n-ditetradecylacetamide; sucrose; distearoylphosphatidylcholine; trometamol; trometamol hydrochloride - active immunisation to prevent coronavirus disease 2019 (covid-19) caused by sars-cov-2, in individuals 12 years of age and older.,the use of this vaccine should be in accordance with official recommendations.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - tozinameran, quantity: 130 microgram - injection, concentrated - excipient ingredients: ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate); water for injections; cholesterol; 2-((polyethylene glycol)-2000)-n-n-ditetradecylacetamide; sucrose; distearoylphosphatidylcholine; trometamol; trometamol hydrochloride - active immunisation to prevent coronavirus disease 2019 (covid-19) caused by sars-cov-2, in individuals 5 years of age to less than 12 years of age.,the use of this vaccine should be in accordance with official recommendations.